postulate the existence of a deformylase, acting at some later step in the pathway.
and XhoI restriction sites (in capital letters), respectively. The product was confirmed by DNA sequencing of pET-ArnADH.
Expression of the ArnA-Formyltransferase and ArnA-Dehydrogenase Domains-
The formyltransferase (pET-ArnAFT) and dehydrogenase domains (pET-ArnADH) of ArnA were expressed in E. coli NovaBlue(DE3) (Novagen), as described above for the ArnA-H6N protein, except that a 2.5 h IPTG induction at 30 °C was used.
Construction of pWSK-ArnA, pWSK-ArnAFT, and pWSK-ArnADH-The inserts in the expression vectors pET-ArnA, pET-ArnAFT, or pET-ArnADH were excised with XbaI and XhoI, and cloned into the same restriction sites of the relatively low-copy vector pWSK29 (32) to generate pWSK-ArnA, pWSK-ArnAFT, and pWSK-ArnADH.
Construction of pSDB300 and pSDB350-To make pSDB300 and pSDB350, we first constructed pSDB100 and pSDB150 ( Supplementary Fig. 1 ) by cloning the ArnADH and ArnAFT encoding genes from pET24b (Table 1) into pET28b, respectively. To generate pSDB100, pET-ArnADH was linearized with XbaI, and a two base fill-in was performed with the Klenow fragment of DNA Pol I in the presence of dCTP and dTTP. The DNA encoding the ArnADH was excised with XhoI and cloned into pET28b, previously prepared with a HindIII digestion, followed by a fill-in reaction with dATP and dGTP using Klenow fragment, and then cut with XhoI ( Supplementary Fig. 1 ). Repeating this procedure with the ArnAFT encoding DNA from pET-ArnAFT (Table 1 ) gave pSDB150. pSDB200 was constructed by excising the ArnAFT encoding DNA from pET-ArnAFT with XbaI and XhoI, and then ligating this fragment into the XbaI and SalI sites of pSDB100 ( Supplementary Fig. 1 ). Similarly, pSDB250 was made by first excising the ArnADH encoding DNA from pET-ArnADH with XbaI and XhoI, and then ligating this into the XbaI and SalI sites of pSDB150 ( Supplementary Fig. 1 ). Ligating the XbaI -XhoI-fragment of pSDB200 into these same restriction sites of pWSK29 resulted in the construction of pSDB300, which contains the arnAFT followed by arnADH, each with a ribosomal binding site derived from pET28b just upstream of the cloned genes. Similarly, pSDB350 was constructed by ligating the XbaI / XhoI-fragment of pSDB250 into these same restriction sites of pWSK29 ( Supplementary Fig. 1 ). pSDB350 contains the arnADH followed by arnAFT, each with a ribosomal binding site derived from pET28b just upstream of the cloned genes.
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Construction of pET-ArnC-The arnC gene was amplified by PCR from E. coli W311O genomic DNA using the primers arnC5 (5′-cggatCCATGGttgaaatccaccctgttaagaaagtc-3′) and arnC3 (5′-cgggatcCTCGAGttattcattttccttgctggatggacg-3′), containing engineered NcoI and XhoI restriction sites (capital letters). The Opti-Prime™ PCR kit (Stratagene) was used.
Amplification in a 50 µl reaction with 10 x Opti-Prime Buffer 6 (100 mM Tris-HCl, pH 8.8, 15 mM MgCl 2 , 750 mM KCl), 0.2 mM dNTP, 200 ng genomic DNA, 0.5 µM primers, and 2.5 units Pfu DNA polymerase for 30 cycles (94 ºC for 1 min, 50 ºC for 1 min, and 72 ºC for 1.5 min), followed by one cycle of (94 ºC for 1 min, 50 ºC for 1 min, and 72 ºC for 10 min), resulted in a single product of the predicted size. The product was isolated with the QIAquick PCR Purification kit (Qiagen), digested with XhoI and NdeI, and ligated into the T7 expression vector, pET28b (Novagen), previously digested with the same enzymes. The product was confirmed by DNA sequencing.
Enzymatic Synthesis and Isolation of Uridine 5′-diphospho-β-(4-amino-4-deoxy-L-
arabinose)-A 5-ml reaction containing 0.1 mg/ml of an E. coli NovaBlue(DE3)/pET-ArnA cellfree extract over-expressing ArnA, 0.05 mg/ml purified ArnBC6H, 1 mM UDP-GlcUA, 3 mM NAD + , and 25 mM L-glutamate in 50 mM HEPES, pH 7.5, supplemented with 2 mM DTT, was incubated at 30 ºC for 4 hours. Protein was removed by passing the reaction mixture through a Centricon® YM-10 membrane. The product was diluted 10-fold with deionized water and loaded onto a 10-ml column of DEAE-Sepharose™ CL6B, pre-equilibrated with 10 mM BisTris, pH 6.0. The column was washed with 50 ml water, followed by elution with a 0 to 100 mM Bis-Tris gradient, pH 6.0 (200 ml total volume). Elution was monitored by measuring A 254 .
Fractions (20 ml) containing the product (eluting at ~30 mM Bis-Tris) were pooled, diluted 10-fold with water, and loaded onto a 10-ml column of DEAE-Sepharose™ CL6B, equilibrated with 10 mM triethylammonium bicarbonate, pH 8.5. The column was washed with 50 ml water, followed by elution with a 0 to 100 mM triethylammonium bicarbonate gradient, pH 8.5 (200 ml total volume). Chromatography was monitored by measuring A 254 . Fractions (25 ml) containing the product (eluting at ~60 mM triethylammonium bicarbonate) were pooled and concentrated by lyophilization to give the triethylammonium salt of UDP-L-Ara4N (1.6 mg, 51% yield). the reaction mixture was diluted to 1.5 ml with water and loaded onto a 2-ml column of DEAESepharose CL-6B, equilibrated in 10 mM Bis-Tris, pH 6.5. The column was washed with 5 ml water, followed by elution with a 0-100 mM Bis-Tris, pH 6.5, gradient (40 ml volume).
Enzymatic Synthesis and Purification of Uridine 5′-diphospho-β-(4-amino-4-deoxy-L-
Fractions containing UDP-[ 14 C-U]-L-Ara4N were pooled, diluted 10-fold with water, and loaded onto a second 2-ml column of DEAE-Sepharose CL-6B, pre-equilibrated with 10 mM triethylammonium bicarbonate, pH 8.5. This column was washed with 5 ml water, followed by a gradient of 0-100 mM triethylammonium bicarbonate, pH 8.5 (40 ml volume). The eluted material was concentrated using a Speed-Vac centrifuge and dissolved in 250 µl of water. The yield was 74% based on radioactivity.
UDP-[ 14 C-U]-L-Ara4FN was generated as follows. A 250 µl reaction containing 24 µM
HEPES, pH 7.5, and 2 mM DTT, was pre-incubated for 30 min at 30 °C before purified ArnA-N6H was added to a final concentration of 0.05 mg/ml. The reaction was allowed to proceed for 180 minutes at 30 °C, then diluted to 3 ml with water, and loaded onto a 2-ml column of DEAESepharose CL-6B, equilibrated in 10 mM Bis-Tris, pH 6.5. The column was washed with 5 ml water, followed by elution with a 0-100 mM Bis-Tris, pH 6.5, gradient (40 ml volume).
Fractions containing UDP-[ 14 C-U]-L-Ara4N were pooled, diluted 10-fold with water, and loaded onto a second 2-ml column of DEAE-Sepharose CL-6B, pre-equilibrated with 10 mM triethylammonium bicarbonate, pH 8.5. This column was washed with 5 ml water, followed by a gradient of 0-100 mM triethylammonium bicarbonate, pH 8.5 (40 ml volume). The eluted material was concentrated using a Speed-Vac centrifuge and dissolved in 200 µl of water. The yield was 84% based on radioactivity.
Enzymatic Synthesis and Isolation of Uridine 5′-diphospho-β-(4-deoxy-4-formamido-Larabinose)-
The reaction mixture for the conversion of UDP-L-Ara4N to UDP-L-Ara4FN contained 0.05 mg/ml pure ArnAN6H, 200 µM UDP-L-Ara4N, 1 mM N -5, N -10-methenyltetrahydrofolate, 2 mM DTT, and 50 mM HEPES, pH 7.5, in 15 ml. After 6 hours at 30 ºC, enzyme was removed by passing the mixture through a Centricon® YM-10 membrane. The sugar nucleotide was loaded onto a 10-ml column of DEAE-Sepharose™ CL6B, equilibrated with 10 mM Bis-Tris, pH 5.9. The column was washed with 50 ml water, followed by elution of the product with a 0-100 mM Bis-Tris, pH 5.9 gradient (200 ml). Chromatography was monitored by absorbance at 254 nm. Fractions containing the product, which eluted at about 60 mM Bis-Tris, were pooled, diluted 10-fold with water, and loaded onto a second 10-ml column of DEAE-Sepharose™ CL6B, equilibrated with 10 mM triethylammonium bicarbonate, pH 8.5.
The column was washed with 50 ml water. The product was eluted with a 0-100 mM gradient of triethylammonium bicarbonate, pH 8.5 (200 ml). Fractions containing the product, which eluted at about 60 mM triethylammonium bicarbonate, were pooled and concentrated by lyophilization to give the triethylammonium salt of the sugar nucleotide. Conversion to the sodium salt was accomplished by passing the material over a small column of AG ® 50W-X8 resin (sodium form).
The overall yield was 55 %. and spotted onto a polyethyleneimine-cellulose TLC plate, which was developed and analyzed as described above.
Assays for ArnA-dehydrogenase at 30 °C were performed with cell-free extract (0.5 mg/ml) in a 20 µl reaction cocktail containing 50 mM HEPES, pH 7.5, 2 mM DTT, 5 mM α- 
Construction of a pmrA c Mutant of E. coli K-12 with an Insertion in the Chromosomal
Copy of arnA-Using a pmrA c derivative of E. coli strain DY-330, designated MST100 (Table 1) ,
we used λ-RED-mediated recombination ( The desired strain, SDB100, was polymyxin sensitive and kanamycin resistant, and it only grew at 30 °C. The entire chromosomal region containing the Kan r insertion in arnA gene was then transduced back into E. coli WD101 (PmrA c ) with a P1vir lysate prepared on SDB100 ( Table 1 ).
The resulting mutant was designated SDB101 (pmrA c ΔarnA::kan r ); it was polymyxin sensitive and kanamycin resistant, and grew at 37 °C. The arnA::kan r replacement on the chromosome of SDB101 was verified by PCR amplification of the arnA region using external primers located 108 bp upstream (p1015: 5'-TATTGGCGCTCAGTTTATCGGC-3') and 58 bp downstream (p1013: 5'-ACTCAAGATTTCCAGCAGACGC-3'). The PCR product was resolved on a 1.5%
agarose gel, purified with the QIAquick Gel Extraction kit (Qiagen), and sequenced using the same primers to confirm the arnA::kan r replacement, and the insertion of the engineered ribosomal binding site. (Fig. 3A, lanes 2 and 3) . N -5 -formyltetrahydrofolate (Fig. 3A, lane 4) was inactive, consistent with the reaction reported previously in crude extracts of polymyxin resistant (pmrA c ) E. coli (25) . The specific activity of the purified ArnA formyltransferase, calculated from the time course (Fig. 3B) , was 100-fold higher than that of extracts of polymyxin resistant cells, and ten fold higher than extracts of the over-producing strain. The formyltransferase was absent in a pmrA c mutant of E. coli in which the arnA gene was replaced with a kanamycin resistance cassette (see below). The results show that arnA is the structural gene for both the formyltransferase and the UDP-GlcUA dehydrogenase. Tables II and III) . However, the signals arising from the pyranose moiety of the putative UDP-L-Ara4FN (Fig. 2 ) show significant differences from those of the substrate UDP-L-Ara4N, especially at H-4′′ (Fig. 5, panel A versus B, and Table II ).
1-Dof N-10-formyl-tetrahydrofolate, as described in "Experimental
In the downfield portion of the 1 H NMR spectrum, sharp singlets are present at 8. (Fig. 4C) . The J HCO,NH coupling constant (1.6 Hz) for the amide proton of the major isomer, and the intramolecular cross-peak between these two protons in an NOE experiment (not shown), confirmed that the major isomer is the cis-formamido rotamer (Fig. 2 ). (Fig. 6 ) allowed definitive assignment of the protons in the ribose, uracil, and pyranose rings. As suggested by the 1-D spectra, the uridine nucleoside moiety was not altered by ArnA (Table II) . Close similarities between the spectra of the putative UDP-L-Ara4FN and UDP-L-Ara4N include the strong cross-peak connectivities between uracil H-6 and H-5 (not shown), ribose H-1′ and H-2′ (~4.38 ppm), ribose H-3′ and H-4′ ( 4.30 ppm), and ribose H-4′ to H-5a′ and H-5b′ (Table II and Fig. 6 ).
2-D 1 H NMR Spectroscopy of the Formyltransferase Product-
The assignments of the pyranose protons of the product are as follows. The anomeric H-1″ proton, a double-doublet at 5.63 ppm (J 1″,2″ = 3.6, J 1″,P = 7.1 Hz), shows a cross-peak to the H- (Table III) The multibond HMBC two-dimensional map (not shown) allows identification of the quaternary carbons (Table III) with E values of 0.003 and 0.003 respectively (52) (53) (54) . This is consistent with the function of ArnA in the oxidative decarboxylation of UDP-GlcUA. All three proteins possess the conserved glycine rich "Rossmann fold", located within the first 13 amino acids of the RmlB and GalE (52, 53) , and between R317 and G330 of ArnA (55).
The sequence alignments and structures suggest that ArnA consists of two independent catalytic domains, connected by a short linker. We therefore cloned and expressed the separate domains in pET28b and pWSK29 ( Table 1 ). The ArnAFT protein consists of the first 304 amino acids of ArnA, with N305 converted to a stop codon. The ArnADH protein consists of the Cterminal 345 residues of ArnA, starting at T316 converted to an initiating methionine. As shown below, the separated domains are active in vitro and in living bacteria.
Both ArnA Domains Are Needed for Polymyxin Resistance and Lipid A Modification-

To determine whether or not formylation of UDP-L-Ara4N is necessary for L-Ara4N
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http://www.jbc.org/ Downloaded from modification of lipid A and maintenance of polymyxin resistance, an in-frame deletion of the chromosomal arnA gene was generated in a pmrA C (polymyxin resistant) background to generate E. coli SBD101 ( Table 1 ). The λ-RED system was used to disrupt the arnA gene (34) Full-length ArnA, ArnADH, ArnAFT, or both ArnADH and ArnAFT were introduced on low copy plasmids into SBD101 by selecting for ampicillin and kanamycin resistance (Table   IV) . The transformants were then tested for their ability to grow in the presence of polymyxin.
Only those constructs expressing both domains of ArnA, either as the intact protein or the separate pieces, were resistant to 10 µg/ml polymyxin on LB plates ( Fig. 8 and Table IV ).
Furthermore, the lipid A of SDB101 lacked the L-Ara4N modification, unless complemented with both domains of ArnA (Table IV) . These experiments show that UDP-L-Ara4FN is an obligatory intermediate in the modification of Lipid A with the L-Ara4N residue. It is not a side product that is used for unrelated glycosylation reactions.
Enzymatic Activity Associated with the ArnA Domains-Simultaneous expression of both disconnected ArnA domains from either pSDB300 or pSDB350 (Tables I and IV, and Supplementary Fig. 1 ) caused SDB101 to regain polymyxin-resistance. To confirm that the isolated domains possessed catalytic activity by themselves, cell-free extracts of the relevant constructs were prepared and assayed. Extracts of SDB101 or SDB101/pWSK29 contained no ArnA dehydrogenase or formyltransferase activity (Fig. 9 ), but ArnB activity (Fig. 2 ) was normal (data not shown). Extracts of SDB101, expressing ArnADH from pWSK-ArnADH, had similar levels of dehydrogenase as the parental strain E. coli WD101, but not quite as much as SDB101 expressing full-length ArnA from pWSK-ArnA (Table IV and Fig. 9, panel A) .
Extracts of SDB101 expressing ArnAFT from pWSK-ArnAFT contained 3-fold higher formyltransferase activity than SBD101 expressing full-length ArnA, or about ~ 75-fold more activity than E. coli WD101 (Tabele IV and Fig. 9 panel B) . When only ArnADH was expressed, dehydrogenase activity was detectable, but formyltransferase was not. Conversely, Fig. 8 and Table 4 ). ArnC(PmrF) itself is likewise needed for both polymyxin resistance and aminoarabinose modification (19, 21) . The reaction catalyzed by ArnC mechanistically resembles the one catalyzed by dolichyl phosphate mannose synthase in eucaryotic cells, which accounts for the distant similarity of the ArnC sequence to the dolichyl phosphate-mannose synthase family, as first noted by Zhou et al. (24) .
Discussion
In E. coli, S. typhimurium and some other pathogenic Gram-negative bacteria, modification of the phosphate groups of lipid A with the L-Ara4N moiety (Fig. 1 ) confers resistance to polymyxin and cationic antimicrobial peptides by reducing the net negative charge of the lipid (18, 19, 21, 22) . The L-Ara4N unit arises from UDP-GlcUA (25, 26) . It is synthesized and attached to lipid A by the pathway shown in Fig. 2 . Six ArnA proteins (previously designated PmrF through K) (19) and Ugd are required for this process. As shown previously,
ArnA catalyzes the oxidative-decarboxylation of UDP-GlcUA to generate a novel UDP-4′′-ketopentose (25) , which ArnB converts to UDP-L-Ara4N (Fig. 2) (26) . The lipid undecaprenyl phosphate-α-L-Ara4N, which accumulates in polymyxin resistant mutants, is then used by ArnT as the donor substrate for transferring the L-Ara4N moiety to lipid A on the outer surface of the inner membrane (16, 17) .
In principle, the most direct pathway for L-Ara4N modification of lipid A would involve the transfer of the L-Ara4N unit from UDP-L-Ara4N directly to undecaprenyl-phosphate by ArnC, followed by its transfer to lipid A. Unexpectedly, however, ArnA is a bifunctional enzyme with a putative N-terminal formyltransferase active site in addition to its C-terminal UDP-GlcUA dehydrogenase activity (25) . We have now shown unequivocally that the Nterminal domain of ArnA catalyzes the N-formylation of UDP-L-Ara4N (Fig. 2, box) , accounting for the formylation UDP-L-Ara4N previously seen in crude extracts of polymyxin resistant (but not wild-type) E. coli (25) . Purified ArnAN6H requires N-10-formyltetrahydrofolate for the modification of UDP-L-Ara4N (Fig. 3) . ArnT, an inner membrane protein with 12 predicted transmembrane segments, transfers the L-Ara4N moiety of undecaprenyl phosphate-α-L-Ara4N to lipid A (16, 17) . Undecaprenyl phosphate-α-L-Ara4N is a well-characterized minor lipid present exclusively in polymyxin resistant strains of E. coli (16, 17) . No formyl group is present either on undecaprenyl phosphate-α-L-Ara4N or on L-Ara4N modified lipid A (13, 16, 17, 24, 61) . Since UDP-L-Ara4N is the product of ArnB, the existence of the formyltransferase domain of ArnA and its product, UDP-LAra4FN, present an interesting conundrum. In principle, UDP-L-Ara4FN might be utilized for a separate glycosylation pathway having nothing to do with lipid A. However, the results of Fig. 8 and Table IV demonstrate Tables II and III . WD101 (▲, 0.5 mg/ml); SDB101 (◆, 0.5 mg/ml); SDB101/pWSK-ArnA (•, 0.05 mg/ml); SDB101/pWSK-ArnADH (■, 0.5 mg/ml); or SDB101/pWSK-ArnAFT (▼, 0.01 mg/ml). At the indicated times 1 µl portions were spotted onto a polyethyleneimine-cellulose plate, which was developed and analyzed as described in the "Experimental Procedures". 
